{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:22:51Z","timestamp":1793244171839,"version":"4.5.0"},"reference-count":287,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DST\/NM\/NT\/2018\/105"],"award-info":[{"award-number":["DST\/NM\/NT\/2018\/105"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["31-2(274)2020\u201321"],"award-info":[{"award-number":["31-2(274)2020\u201321"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-40"],"award-info":[{"award-number":["HCP-40"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/2017\/000992\/HS & EMR\/2017\/001183"],"award-info":[{"award-number":["EMR\/2017\/000992\/HS & EMR\/2017\/001183"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012323","name":"CSIR-Indian Institute of Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.gendis.2022.07.024","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T23:51:08Z","timestamp":1661298668000},"page":"1318-1350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Targeting PD-1\/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients"],"prefix":"10.1016","volume":"10","author":[{"given":"Sunny","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouli","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyasha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirat K.","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-3065","authenticated-orcid":false,"given":"Mrinal K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1673","key":"10.1016\/j.gendis.2022.07.024_bib1","doi-asserted-by":"crossref","first-page":"20140219","DOI":"10.1098\/rstb.2014.0219","article-title":"Cancer across the tree of life: cooperation and cheating in multicellularity","volume":"370","author":"Aktipis","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7501","key":"10.1016\/j.gendis.2022.07.024_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(67)92837-1","article-title":"Immunological aspects of malignant disease","volume":"1","author":"Burnet","year":"1967","journal-title":"Lancet"},{"issue":"3950","key":"10.1016\/j.gendis.2022.07.024_bib3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science"},{"issue":"5256","key":"10.1016\/j.gendis.2022.07.024_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"issue":"18","key":"10.1016\/j.gendis.2022.07.024_bib7","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/anie.201710407","article-title":"Immune checkpoint PD-1\/PD-L1: is there life beyond antibodies?","volume":"57","author":"Konstantinidou","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"issue":"30","key":"10.1016\/j.gendis.2022.07.024_bib8","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2","volume":"105","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib9","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib10","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib11","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib12","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1128\/JVI.02131-09","article-title":"E1A interacts with two opposing transcriptional pathways to induce quiescent cells into S phase","volume":"84","author":"Sha","year":"2010","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"issue":"6440","key":"10.1016\/j.gendis.2022.07.024_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 binds to B7-1 only in cis on the same cell surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-13-0204","article-title":"A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation","volume":"2","author":"Haile","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib18","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.4049\/jimmunol.1003976","article-title":"B7-h1 expressed by activated CD8 T cells is essential for their survival","volume":"187","author":"Pulko","year":"2011","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib19","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.gendis.2022.07.024_bib21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3389\/fimmu.2019.02178","article-title":"Tumors vs. chronic wounds: an immune cell's perspective","volume":"10","author":"Hua","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2119\/molmed.2015.00083","article-title":"Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy","volume":"21","author":"Lin","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.gendis.2022.07.024_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.placenta.2017.03.010","article-title":"Hypoxia and HIF pathway in cancer and the placenta","volume":"56","author":"Macklin","year":"2017","journal-title":"Placenta"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/08830180215017","article-title":"Immunological relationship between the mother and the fetus","volume":"21","author":"Szekeres-Bartho","year":"2002","journal-title":"Int Rev Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/imm.12866","article-title":"Cancer stem cells as targets for immunotherapy","volume":"153","author":"Codd","year":"2018","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib26","doi-asserted-by":"crossref","first-page":"180081","DOI":"10.1098\/rsob.180081","article-title":"Exploring the links between cancer and placenta development","volume":"8","author":"Costanzo","year":"2018","journal-title":"Open Biol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib27","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.gendis.2021.08.003","article-title":"Chaperone-assisted E3 ligase CHIP: a double agent in cancer","volume":"9","author":"Kumar","year":"2021","journal-title":"Genes Dis"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib28","doi-asserted-by":"crossref","first-page":"1731942","DOI":"10.1080\/2162402X.2020.1731942","article-title":"Lactate dehydrogenase: a marker of diminished antitumor immunity","volume":"9","author":"Van Wilpe","year":"2020","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib29","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gendis.2022.07.024_bib31","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2020.04.044","article-title":"Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells","volume":"147","author":"Quatrini","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib33","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","article-title":"Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib34","doi-asserted-by":"crossref","first-page":"e0119200","DOI":"10.1371\/journal.pone.0119200","article-title":"Programmed death 1 regulates memory phenotype CD4 T cell accumulation, inhibits expansion of the effector memory phenotype subset and modulates production of effector cytokines","volume":"10","author":"Charlton","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.gendis.2022.07.024_bib35","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4049\/jimmunol.108.3.586","article-title":"Suppressor T cells","volume":"108","author":"Gershon","year":"1972","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib38","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.4049\/jimmunol.129.5.2293","article-title":"Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody","volume":"129","author":"Allison","year":"1982","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib39","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.2046fta","article-title":"CTLA-4: from conflict to clinic","volume":"204","author":"Bashyam","year":"2007","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0167-5699(94)90080-9","article-title":"The B7 and CD28 receptor families","volume":"15","author":"June","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.gendis.2022.07.024_bib42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"22","key":"10.1016\/j.gendis.2022.07.024_bib43","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib44","first-page":"503","article-title":"Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use","volume":"37","author":"Fellner","year":"2012","journal-title":"P T"},{"issue":"5502","key":"10.1016\/j.gendis.2022.07.024_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib46","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib51","doi-asserted-by":"crossref","first-page":"e12731","DOI":"10.1111\/sji.12731","article-title":"Seminal immunologic discoveries with direct clinical implications: the 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy","volume":"88","author":"Ljunggren","year":"2018","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.gendis.2022.07.024_bib52","doi-asserted-by":"crossref","first-page":"670900","DOI":"10.3389\/fphar.2021.670900","article-title":"Trends in the research into immune checkpoint blockade by anti-PD1\/PDL1 antibodies in cancer immunotherapy: a bibliometric study","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7528","key":"10.1016\/j.gendis.2022.07.024_bib53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"7528","key":"10.1016\/j.gendis.2022.07.024_bib56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"issue":"6230","key":"10.1016\/j.gendis.2022.07.024_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1158\/2326-6066.CIR-16-0110","article-title":"Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups","volume":"4","author":"de Velasco","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"6230","key":"10.1016\/j.gendis.2022.07.024_bib59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2015.39","article-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance","volume":"18","author":"Martin","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib61","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib62","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-014-0036-y","article-title":"Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells","volume":"2","author":"Pollack","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2022.07.024_bib64","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/jco.2015.33.15_suppl.3021","article-title":"Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1","volume":"33","author":"Somaiah","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib65","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"7559","key":"10.1016\/j.gendis.2022.07.024_bib66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib68","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"279","key":"10.1016\/j.gendis.2022.07.024_bib69","doi-asserted-by":"crossref","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib71","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.tibs.2013.06.003","article-title":"The MHC I loading complex: a multitasking machinery in adaptive immunity","volume":"38","author":"Hulpke","year":"2013","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib74","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"7806","key":"10.1016\/j.gendis.2022.07.024_bib75","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib76","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.gendis.2022.07.024_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib78","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.11618","article-title":"CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression","volume":"98","author":"Sasada","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib79","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"issue":"34","key":"10.1016\/j.gendis.2022.07.024_bib80","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.gendis.2022.07.024_bib81","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","article-title":"A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1","volume":"75","author":"Ngiow","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib83","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib84","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib85","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamaoncol.2016.6108","article-title":"Comparison of prevalence and types of mutations in lung cancers among black and white populations","volume":"3","author":"Campbell","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib87","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/15384047.2016.1156256","article-title":"PD-1\/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR\/KRAS mutations","volume":"17","author":"Ji","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"6024","key":"10.1016\/j.gendis.2022.07.024_bib88","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib89","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.prp.2018.11.014","article-title":"Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma","volume":"215","author":"Yeon","year":"2019","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib91","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib92","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib93","doi-asserted-by":"crossref","first-page":"e1564505","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib94","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1172\/JCI133055","article-title":"A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy","volume":"130","author":"Theivanthiran","year":"2020","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.21147\/j.issn.1000-9604.2018.02.01","article-title":"Future of anti-PD-1\/PD-L1 applications: combinations with other therapeutic regimens","volume":"30","author":"Song","year":"2018","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib96","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s42003-020-0811-x","article-title":"Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens","volume":"3","author":"Grimaldi","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.gendis.2022.07.024_bib97","doi-asserted-by":"crossref","first-page":"108632","DOI":"10.1016\/j.biopha.2019.108632","article-title":"Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma","volume":"112","author":"Shi","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"10.1016\/j.gendis.2022.07.024_bib98","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib99","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00262-008-0628-9","article-title":"Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy","volume":"58","author":"van der Most","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.gendis.2022.07.024_bib100","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib101","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7662","key":"10.1016\/j.gendis.2022.07.024_bib102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2022.07.024_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front Oncol"},{"issue":"15_Suppl","key":"10.1016\/j.gendis.2022.07.024_bib104","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7547","key":"10.1016\/j.gendis.2022.07.024_bib105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2022.07.024_bib106","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3389\/fimmu.2018.03154","article-title":"Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment","volume":"9","author":"Darragh","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib107","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib108","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.celrep.2017.05.015","article-title":"A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy","volume":"19","author":"Takeda","year":"2017","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib109","doi-asserted-by":"crossref","first-page":"e1659096","DOI":"10.1080\/2162402X.2019.1659096","article-title":"Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors","volume":"8","author":"Kapp","year":"2019","journal-title":"OncoImmunology"},{"issue":"25","key":"10.1016\/j.gendis.2022.07.024_bib110","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMc1714339","article-title":"Nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib111","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib113","doi-asserted-by":"crossref","first-page":"e0119483","DOI":"10.1371\/journal.pone.0119483","article-title":"Blockade of PD-1\/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment","volume":"10","author":"Blake","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib115","doi-asserted-by":"crossref","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"OncoImmunology"},{"issue":"21","key":"10.1016\/j.gendis.2022.07.024_bib116","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1158\/0008-5472.CAN-16-2141","article-title":"Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor","volume":"76","author":"Ngiow","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fcell.2018.00038","article-title":"Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors","volume":"6","author":"Cassetta","year":"2018","journal-title":"Front Cell Dev Biol"},{"issue":"18","key":"10.1016\/j.gendis.2022.07.024_bib118","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib119","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7693","key":"10.1016\/j.gendis.2022.07.024_bib120","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.gendis.2022.07.024_bib121","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"237","key":"10.1016\/j.gendis.2022.07.024_bib122","doi-asserted-by":"crossref","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7629","key":"10.1016\/j.gendis.2022.07.024_bib123","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"issue":"7577","key":"10.1016\/j.gendis.2022.07.024_bib124","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2022.07.024_bib125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or Ido blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib126","doi-asserted-by":"crossref","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the tumor microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"OncoImmunology"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib127","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib128","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","article-title":"A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models","volume":"6","author":"Willingham","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib129","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib131","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib132","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"issue":"6371","key":"10.1016\/j.gendis.2022.07.024_bib133","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib134","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib135","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1309\/AJCPIV9IQ1MRQMOO","article-title":"Molecular pathology of breast cancer: what a pathologist needs to know","volume":"138","author":"Allison","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib136","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199207303270505","article-title":"Breast cancer (1)","volume":"327","author":"Harris","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib137","doi-asserted-by":"crossref","first-page":"djw192","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib138","doi-asserted-by":"crossref","first-page":"14356","DOI":"10.1038\/s41598-019-50898-3","article-title":"Expression of PD-1\/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters","volume":"9","author":"Yuan","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib139","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib141","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11523-018-0610-1","article-title":"PD-1 and PD-L1 expression in male breast cancer in comparison with female breast cancer","volume":"13","author":"Manson","year":"2018","journal-title":"Targeted Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib142","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-017-0627-0","article-title":"Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1","volume":"19","author":"Bertucci","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib143","first-page":"4249","article-title":"Clinical significance of PD1 and PDL1 in human breast cancer","volume":"37","author":"Uhercik","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42047-019-0033-z","article-title":"Expression of PD-L1 in primary breast carcinoma and lymph node metastases","volume":"2","author":"Alves","year":"2019","journal-title":"Surg Exp Pathol"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib145","doi-asserted-by":"crossref","first-page":"e1500107","DOI":"10.1080\/2162402X.2018.1500107","article-title":"Adipose PD-L1 modulates PD-1\/PD-L1 checkpoint blockade immunotherapy efficacy in breast cancer","volume":"7","author":"Wu","year":"2018","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib146","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative breast cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib147","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14728222.2018.1471137","article-title":"Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells","volume":"22","author":"Sasidharan Nair","year":"2018","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib148","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/cancers11101479","article-title":"STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer","volume":"11","author":"Zerdes","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2022.07.024_bib149","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13148-018-0512-1","article-title":"DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer","volume":"10","author":"Sasidharan Nair","year":"2018","journal-title":"Clin Epigenet"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib150","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/cancers13092207","article-title":"TET2 inhibits PD-L1 gene expression in breast cancer cells through histone deacetylation","volume":"13","author":"Shen","year":"2021","journal-title":"Cancers"},{"issue":"69","key":"10.1016\/j.gendis.2022.07.024_bib151","doi-asserted-by":"crossref","first-page":"114156","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer","volume":"8","author":"Terranova-Barberio","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib152","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib153","first-page":"1837","article-title":"Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer","volume":"8","author":"Shao","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib154","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/IGC.0000000000000875","article-title":"Posttranscriptional control of PD-L1 expression by 17\u03b2-estradiol via PI3K\/Akt signaling pathway in ER\u03b1-positive cancer cell lines","volume":"27","author":"Yang","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.gendis.2022.07.024_bib155","first-page":"3958908","article-title":"PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications","volume":"2019","author":"Darvin","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib156","doi-asserted-by":"crossref","first-page":"e1376155","DOI":"10.1080\/2162402X.2017.1376155","article-title":"Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer","volume":"7","author":"Kumar","year":"2018","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib157","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","article-title":"Palmitoylation stabilizes PD-L1 to promote breast tumor growth","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib158","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1158\/0008-5472.CAN-17-1636","article-title":"MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer","volume":"78","author":"Maeda","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib159","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","article-title":"Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion","volume":"40","author":"Fang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2022.07.024_bib160","doi-asserted-by":"crossref","first-page":"24706","DOI":"10.18632\/oncotarget.14960","article-title":"Cancer-associated oxidoreductase ERO1-\u03b1 promotes immune escape through up-regulation of PD-L1 in human breast cancer","volume":"8","author":"Tanaka","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2018.09.005","article-title":"ER\u03b1 is a negative regulator of PD-L1 gene transcription in breast cancer","volume":"505","author":"Liu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"59","key":"10.1016\/j.gendis.2022.07.024_bib162","doi-asserted-by":"crossref","first-page":"99901","DOI":"10.18632\/oncotarget.21914","article-title":"PD-1\/PD-L1 interaction up-regulates MDR1\/P-gp expression in breast cancer cells via PI3K\/AKT and MAPK\/ERK pathways","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib163","first-page":"282","article-title":"PERK-phosphorylated eIF2\u03b1 pathway suppresses tumor metastasis through downregulating expression of programmed death ligand 1 and CXCL5 in triple-negative breast cancer","volume":"32","author":"Zou","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib164","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-018-4833-8","article-title":"Syntenin1\/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1","volume":"171","author":"Liu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.gendis.2022.07.024_bib165","doi-asserted-by":"crossref","first-page":"32722","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/j.gendis.2022.07.024_bib166","doi-asserted-by":"crossref","first-page":"42414","DOI":"10.18632\/oncotarget.17123","article-title":"Type I\u03b3 phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-\u03baB","volume":"8","author":"Xue","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib167","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41419-021-03745-1","article-title":"Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1-PD-L1+ Bregs through PD-L1\/PI3K\/AKT\/NF-\u03baB axis in breast cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib168","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX regulates tumor-mediated immunosuppression by controlling EGFR activity and PD-L1 presentation","volume":"24","author":"Monypenny","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib169","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41467-020-15364-z","article-title":"NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer","volume":"11","author":"Qin","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.gendis.2022.07.024_bib170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2019.08.013","article-title":"BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response","volume":"465","author":"Andrieu","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2022.07.024_bib171","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","article-title":"Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells","volume":"14","author":"Alsuliman","year":"2015","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib172","doi-asserted-by":"crossref","first-page":"1729299","DOI":"10.1080\/2162402X.2020.1729299","article-title":"PD-L1 is overexpressed on breast cancer stem cells through notch3\/mTOR axis","volume":"9","author":"Mansour","year":"2020","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib173","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ijc.30834","article-title":"PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation","volume":"141","author":"Almozyan","year":"2017","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.gendis.2022.07.024_bib174","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1038\/s41388-019-0700-2","article-title":"WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer","volume":"38","author":"Castagnoli","year":"2019","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib175","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3390\/cancers13051165","article-title":"Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib176","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib177","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/cancers12030636","article-title":"Crosstalk between HER2 and PD-1\/PD-L1 in breast cancer: from clinical applications to mathematical models","volume":"12","author":"Padmanabhan","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib178","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/cancers12010094","article-title":"Impact of FAK expression on the cytotoxic effects of CIK therapy in triple-negative breast cancer","volume":"12","author":"Pan","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib179","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res"},{"issue":"31","key":"10.1016\/j.gendis.2022.07.024_bib180","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1038\/s41388-021-01896-1","article-title":"Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer","volume":"40","author":"Qiu","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib181","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/carcin\/bgaa092","article-title":"Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer","volume":"42","author":"Chatterjee","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.gendis.2022.07.024_bib182","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3389\/fimmu.2020.02026","article-title":"Cancer-associated fibroblasts-derived exosomes suppress immune cell function in breast cancer via the miR-92\/PD-L1 pathway","volume":"11","author":"Dou","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib183","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13046-017-0593-2","article-title":"PDL1 and LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a","volume":"36","author":"Huang","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib184","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","article-title":"MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells","volume":"41","author":"Gao","year":"2019","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib185","doi-asserted-by":"crossref","first-page":"e1263412","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib186","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00262-019-02437-2","article-title":"Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells","volume":"69","author":"Romero","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib187","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yexcr.2019.03.025","article-title":"miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint","volume":"380","author":"Li","year":"2019","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib188","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4048\/jbc.2018.21.e60","article-title":"miR-195\/miR-497 regulate CD274 expression of immune regulatory ligands in triple-negative breast cancer","volume":"21","author":"Yang","year":"2018","journal-title":"J Breast Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib189","doi-asserted-by":"crossref","first-page":"E1511","DOI":"10.3390\/cells9061511","article-title":"Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer","volume":"9","author":"Kansara","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib190","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/15476286.2020.1767455","article-title":"LncRNAs as tumor cell intrinsic factors that affect cancer immunotherapy","volume":"17","author":"Egranov","year":"2020","journal-title":"RNA Biol"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib191","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12282-020-01048-5","article-title":"lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer","volume":"27","author":"Zhang","year":"2020","journal-title":"Breast Cancer"},{"key":"10.1016\/j.gendis.2022.07.024_bib192","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3389\/fonc.2019.01459","article-title":"XIST and TSIX: novel cancer immune biomarkers in PD-L1-overexpressing breast cancer patients","volume":"9","author":"Salama","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib193","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3892\/ol.2021.12854","article-title":"Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes","volume":"22","author":"Samir","year":"2021","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib194","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1002\/jcp.30234","article-title":"LncRNA HEIH\/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production","volume":"236","author":"Nafea","year":"2021","journal-title":"J Cell Physiol"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib195","doi-asserted-by":"crossref","first-page":"e12855","DOI":"10.1111\/cpr.12855","article-title":"LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1","volume":"53","author":"Zhang","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.gendis.2022.07.024_bib196","first-page":"357485","article-title":"Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis","volume":"2015","author":"Zhang","year":"2015","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib197","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib198","doi-asserted-by":"crossref","first-page":"118526","DOI":"10.1016\/j.bbamcr.2019.118526","article-title":"Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions","volume":"1866","author":"Azadi","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"7","key":"10.1016\/j.gendis.2022.07.024_bib199","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cancers11071033","article-title":"PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging. A literature review","volume":"11","author":"Planes-Laine","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib200","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers11081050","article-title":"PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer","volume":"11","author":"Saleh","year":"2019","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.gendis.2022.07.024_bib201","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib202","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000453569","article-title":"PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer","volume":"11","author":"Hartkopf","year":"2016","journal-title":"Breast Care"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-020-2313-7","article-title":"PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh\/Tfr ratio and B-cell maturation during allogeneic pregnancy","volume":"11","author":"Zeng","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2022.07.024_bib204","doi-asserted-by":"crossref","first-page":"561793","DOI":"10.3389\/fimmu.2021.561793","article-title":"Triple-negative breast cancer: intact mismatch repair and partial co-expression of PD-L1 and LAG-3","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D'Amico","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib206","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/21645515.2015.1076953","article-title":"Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12","volume":"12","author":"Bozeman","year":"2016","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib207","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","article-title":"Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib208","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41593-019-0430-3","article-title":"Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression","volume":"22","author":"Kamiya","year":"2019","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.gendis.2022.07.024_bib209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fphar.2020.00251","article-title":"(-)-Sativan inhibits tumor development and regulates miR-200c\/PD-L1 in triple negative breast cancer cells","volume":"11","author":"Peng","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib211","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18632\/aging.102646","article-title":"Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity","volume":"12","author":"Verdura","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.gendis.2022.07.024_bib212","doi-asserted-by":"crossref","first-page":"119353","DOI":"10.1016\/j.lfs.2021.119353","article-title":"Oleuropin controls miR-194\/XIST\/PD-L1 loop in triple negative breast cancer: new role of nutri-epigenetics in immune-oncology","volume":"277","author":"Hamed","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.gendis.2022.07.024_bib213","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2147\/OTT.S159481","article-title":"Albumin\/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib214","doi-asserted-by":"crossref","first-page":"1729300","DOI":"10.1080\/2162402X.2020.1729300","article-title":"Oncolytic poxvirus CF33-hNIS-\u0394F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model","volume":"9","author":"Chaurasiya","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.gendis.2022.07.024_bib215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.gendis.2022.07.024_bib216","doi-asserted-by":"crossref","first-page":"vi300","DOI":"10.1093\/annonc\/mdw374.18","article-title":"Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC)","volume":"27","author":"Infante","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.gendis.2022.07.024_bib218","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.20.02923","article-title":"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"39","author":"Alva","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib219","author":"American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib221","author":"Merck Sharp & Dohme Corp"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib222","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib224","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.gendis.2022.07.024_bib226","doi-asserted-by":"crossref","unstructured":"Sharma P, Abramson VG, O'Dea A, et\u00a0al. Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC). J Clin Oncol. 39(15_suppl):1076.","DOI":"10.1200\/JCO.2021.39.15_suppl.1076"},{"issue":"4_suppl ment","key":"10.1016\/j.gendis.2022.07.024_bib228","article-title":"Abstract P3-09-10: a phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)","volume":"80","author":"Barroso-Sousa","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib229","author":"Tolaney"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2022.07.024_bib235","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1200\/JCO.2020.38.15_suppl.1076","article-title":"A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression","volume":"38","author":"Chien","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib237","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib239","series-title":"Abstract PS12-07: Lenvatinib Plus Pembrolizumab for Previously Treated, Advanced Triple-Negative Breast Cancer: Early Results from the Multicohort Phase 2 LEAP-005 Study","author":"Chung","year":"2021"},{"key":"10.1016\/j.gendis.2022.07.024_bib240","author":"Merck Sharp & Dohme Corp"},{"key":"10.1016\/j.gendis.2022.07.024_bib241","series-title":"Results of ENCORE 602 (TRIO025), a Phase II, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study of Atezolizumab with or without Entinostat in Patients with Advanced Triple-Negative Breast Cancer (aTNBC)","author":"O'Shaughnessy","year":"2020"},{"key":"10.1016\/j.gendis.2022.07.024_bib243","author":"Pfizer"},{"key":"10.1016\/j.gendis.2022.07.024_bib244","series-title":"Feasibility of Real-Time Serial Comprehensive Tumor Analytics: Pilot Study of Olaparib and Durvalumab in Metastatic Triple Negative Breast Cancer (mTNBC)","author":"Li","year":"2020"},{"key":"10.1016\/j.gendis.2022.07.024_bib245","author":"ZM MD"},{"key":"10.1016\/j.gendis.2022.07.024_bib246","author":"BerGenBio"},{"key":"10.1016\/j.gendis.2022.07.024_bib248","author":"Merck Sharp & Dohme Corp"},{"key":"10.1016\/j.gendis.2022.07.024_bib250","author":"Hoffmann-La Roche"},{"key":"10.1016\/j.gendis.2022.07.024_bib251","author":"Hoffmann-La Roche"},{"issue":"5_suppl","key":"10.1016\/j.gendis.2022.07.024_bib256","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.2018.36.5_suppl.206","article-title":"A phase 1 study of p53MVA vaccine in combination with pembrolizumab","volume":"36","author":"Chung","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib257","author":"City of Hope Medical Center"},{"key":"10.1016\/j.gendis.2022.07.024_bib258","author":"PhD SJI"},{"key":"10.1016\/j.gendis.2022.07.024_bib260","author":"PhD SJI"},{"key":"10.1016\/j.gendis.2022.07.024_bib261","author":"Washington University School of Medicine"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib266","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib267","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.annonc.2020.02.003","article-title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","volume":"31","author":"Adams","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib268","doi-asserted-by":"crossref","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","article-title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib269","first-page":"100234","article-title":"Abemaciclib in combination with pembrolizumab for stage IV KRAS-mutant or squamous NSCLC: a phase 1b study","volume":"2","author":"Pujol","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2022.07.024_bib270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.2018.36.15_suppl.1033","article-title":"Safety and efficacy of pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC)","volume":"36","author":"Page","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib271","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gendis.2022.07.024_bib272","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib273","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","article-title":"Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib\/II study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib274","series-title":"Adaptive Phase II Randomized Trial of Nivolumab after Induction Treatment in Triple Negative Breast Cancer (TONIC Trial): Final Response Data Stage I and First Translational Data","author":"Kok","year":"2018"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib275","doi-asserted-by":"crossref","first-page":"e001261","DOI":"10.1136\/jitc-2020-001261","article-title":"Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC","volume":"8","author":"Massa","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib276","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/0284186X.2017.1400180","article-title":"Triple negative breast cancer - prognostic role of immune-related factors: a systematic review","volume":"57","author":"Stovgaard","year":"2018","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib277","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib278","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cellsig.2016.03.007","article-title":"Estrogen receptor alpha transcriptionally activates casein kinase 2 alpha: a pivotal regulator of promyelocytic leukaemia protein (PML) and AKT in oncogenesis","volume":"28","author":"Das","year":"2016","journal-title":"Cell Signal"},{"issue":"9","key":"10.1016\/j.gendis.2022.07.024_bib279","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41419-019-1889-2","article-title":"Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis","volume":"10","author":"Datta","year":"2019","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib280","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cells10010046","article-title":"Tumor suppressors having oncogenic functions: the double agents","volume":"10","author":"Datta","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.gendis.2022.07.024_bib281","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib282","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12094-015-1391-y","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.07.024_bib283","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib284","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.gendis.2022.07.024_bib285","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib286","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"PD-L1 status in breast cancer: current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.gendis.2022.07.024_bib287","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib288","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","article-title":"Association between genomic metrics and immune infiltration in triple-negative breast cancer","volume":"3","author":"Karn","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib289","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers","volume":"10","author":"Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.gendis.2022.07.024_bib290","series-title":"Association of Tumor Mutational Burden (TMB) and Clinical Outcomes with Pembrolizumab (Pembro) versus Chemotherapy (Chemo) in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC) from KEYNOTE-119","author":"Winer","year":"2020"},{"issue":"14","key":"10.1016\/j.gendis.2022.07.024_bib291","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-18-0468","article-title":"Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer","volume":"25","author":"Kraya","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib292","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib293","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gendis.2022.07.024_bib294","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2020.07.044","article-title":"CAR T-cell therapy for triple-negative breast cancer: where we are","volume":"491","author":"Xie","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2022.07.024_bib295","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","article-title":"CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2022.07.024_bib296","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib297","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1535-7163.MCT-20-0385","article-title":"Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer","volume":"19","author":"Dees","year":"2020","journal-title":"Mol Cancer Therapeut"},{"issue":"12","key":"10.1016\/j.gendis.2022.07.024_bib298","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib299","series-title":"Phase I Trial of Autologous cMET-Directed CAR-T Cells Administered Intravenously in Patients with Melanoma & Breast Carcinoma","author":"Shah","year":"2020"},{"issue":"3","key":"10.1016\/j.gendis.2022.07.024_bib300","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"10.1016\/j.gendis.2022.07.024_bib301","doi-asserted-by":"crossref","first-page":"126345","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"issue":"4_suppl l","key":"10.1016\/j.gendis.2022.07.024_bib302","article-title":"Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)","volume":"79","author":"Specht","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2022.07.024_bib303","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.gendis.2022.07.024_bib304","doi-asserted-by":"crossref","first-page":"4795171","DOI":"10.1155\/2020\/4795171","article-title":"Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer","volume":"2020","author":"Zhao","year":"2020","journal-title":"BioMed Res Int"},{"issue":"23","key":"10.1016\/j.gendis.2022.07.024_bib305","doi-asserted-by":"crossref","first-page":"11054","DOI":"10.18632\/aging.102510","article-title":"EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC","volume":"11","author":"Liu","year":"2019","journal-title":"Aging"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib306","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.gendis.2022.07.024_bib307","doi-asserted-by":"crossref","first-page":"e0224015","DOI":"10.1371\/journal.pone.0224015","article-title":"TEM8\/ANTXR1-specific CAR T cells mediate toxicity in vivo","volume":"14","author":"Petrovic","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.gendis.2022.07.024_bib308","series-title":"Evaluation of SSEA-4 as a CAR T Cell Therapeutic Target for the Treatment of Chemoresistant Triple Negative Breast Cancers","author":"Pfeifer","year":"2018"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib309","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-016-0285-y","article-title":"Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level","volume":"9","author":"Song","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib310","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","article-title":"Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells","volume":"11","author":"Han","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2022.07.024_bib311","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1002\/acg2.11","article-title":"CAR T cells targeting \u03b1v\u03b23 integrin are effective against advanced cancer in preclinical models","volume":"1","author":"Wallstabe","year":"2018","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.gendis.2022.07.024_bib312","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.gendis.2022.07.024_bib313","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.3390\/ijms20235942","article-title":"CSPG4 as target for CAR-T-cell therapy of various tumor entities-merits and challenges","volume":"20","author":"Harrer","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"13_Suppl","key":"10.1016\/j.gendis.2022.07.024_bib314","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1158\/1538-7445.AM2019-2322","article-title":"Abstract 2322: ICAM-1 targeting CAR T cell therapy for triple negative breast cancer","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2022.07.024_bib315","doi-asserted-by":"crossref","first-page":"1683345","DOI":"10.1080\/2162402X.2019.1683345","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2020","journal-title":"OncoImmunology"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222002239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222002239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:36:01Z","timestamp":1762450561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304222002239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":287,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2352304222002239"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2022.07.024","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PD-1\/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2022.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}